2. Signaling Pathways
  3. Immunology/Inflammation
  4. CD73
  5. CD73 Inhibitor

CD73 Inhibitor

CD73 Inhibitors (31):

Cat. No. Product Name Effect Purity
  • HY-125286
    AB-680
    		Inhibitor 99.81%
    AB-680 is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73, displays >10,000-fold selectivity over related ecto-nucleotidases CD39. Anti-tumor activity.
  • HY-100747
    PSB-12379
    		Inhibitor 99.54%
    PSB-12379, a nucleotide analogue, is a potent Ecto-5'-Nucleotidase (CD73) inhibitor with Kis of 9.03 nM (rat) and 2.21 nM (human).
  • HY-P99039
    Oleclumab
    		Inhibitor 99.80%
    Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity.
  • HY-137246
    CD73-IN-3
    		Inhibitor 99.89%
    CD73-IN-3 is a potent CD73 inhibitor (IC50=7.3 nM in Calu6 human cell assay). CD73-IN-3, example 2 extracted from patent WO2019168744 A1, has the potential for cancer research.
  • HY-136978
    OP-5244
    		Inhibitor 99.07%
    OP-5244 is a potent and orally active inhibitor of CD73, with an IC50 of 0.25 nM. OP-5244 reverses immunosuppression through blocking of adenosine production, and has the potential for the cancer research.
  • HY-160696
    ORIC-533
    		Inhibitor
    ORIC-533 is an orally active, selective CD73 inhibitor with AMP-competition. ORIC-533 restores immunosuppressed CD8+ T cell proliferation and activation, triggers significant lysis and cell death of multiple myeloma cells in the bone marrow microenvironment.
  • HY-P99181
    Mupadolimab
    		Inhibitor 99.43%
    Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73POS B cells.
  • HY-112502C
    MethADP triammonium
    		Inhibitor 99.03%
    MethADP (Adenosine 5'-(α,β-methylene)diphosphate) triammonium is a CD73 inhibitor. MethADP can be used for the research of ATP-adenosine pathway.
  • HY-112502
    MethADP
    		Inhibitor ≥99.0%
    MethADP is a specific CD73 inhibitor.
  • HY-103695
    CD73-IN-1
    		Inhibitor 99.46%
    CD73-IN-1 is an inhibitor of CD73 which can be used in the treatment of cancer extracted from patent WO 2017153952 A1, example 80.
  • HY-P99169
    Uliledlimab
    		Inhibitor 99.35%
    Uliledlimab is a potent against CD73 humanizedized monoclonal antibody. Uliledlimab inhibits the conversion of extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab can be used in research of cancer.
  • HY-131967
    CD73-IN-4
    		Inhibitor 99.21%
    CD73-IN-4 is a potent and selective methylenephosphonic acid CD73 inhibitor, with an IC50 of 2.6 nM for human CD73. CD73-IN-4 is potential for the research of cancer immunology.
  • HY-145334
    CD73-IN-5
    		Inhibitor 98.14%
    CD73-IN-5 is a potent and selective non-nucleotide small molecule inhibitor of CD73 (IC50 = 19 nM).
  • HY-136978A
    OP-5244 sodium
    		Inhibitor 98.28%
    OP-5244 sodium is a potent and orally active inhibitor of CD73, with an IC50 of 0.25 nM. OP-5244 sodium reverses immunosuppression through blocking of adenosine production, and has the potential for the cancer research.
  • HY-125286A
    AB-680 ammonium
    		Inhibitor
    AB-680 ammonium is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73, displays >10,000-fold selectivity over related ecto-nucleotidases CD39. Anti-tumor activity.
  • HY-112502B
    MethADP sodium salt
    		Inhibitor
    MethADP (sodium salt) is a specific CD73 inhibitor.
  • HY-147592
    CD73-IN-11
    		Inhibitor
    CD73-IN-11 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-11 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022068929A1, compound 24).
  • HY-131435
    CD73-IN-2
    		Inhibitor
    CD73-IN-2 is a potent CD73 inhibitor extracted from WO2020151707A1, example 1, has an IC50 of 0.09 nM.
  • HY-147591
    CD73-IN-10
    		Inhibitor
    CD73-IN-10 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-10 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022068929A1, compound 4).
  • HY-147594
    CD73-IN-13
    		Inhibitor
    CD73-IN-13 is a potent inhibitor of CD73. CD73 is closely associated with tumor growth, angiogenesis and metastasis. CD73-IN-13 be used for preparing a medicament for tumor-related diseases (extracted from patent CN114437039A, compound 7).